ATE185487T1 - Verfahren zur hemmung der viralen morphogenese - Google Patents

Verfahren zur hemmung der viralen morphogenese

Info

Publication number
ATE185487T1
ATE185487T1 AT93914329T AT93914329T ATE185487T1 AT E185487 T1 ATE185487 T1 AT E185487T1 AT 93914329 T AT93914329 T AT 93914329T AT 93914329 T AT93914329 T AT 93914329T AT E185487 T1 ATE185487 T1 AT E185487T1
Authority
AT
Austria
Prior art keywords
inhibiting viral
inhibiting
viral morphogenesis
morphogenesis
viral
Prior art date
Application number
AT93914329T
Other languages
English (en)
Inventor
Jeffrey S Glenn
Original Assignee
Jeffrey S Glenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeffrey S Glenn filed Critical Jeffrey S Glenn
Application granted granted Critical
Publication of ATE185487T1 publication Critical patent/ATE185487T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT93914329T 1992-05-29 1993-06-01 Verfahren zur hemmung der viralen morphogenese ATE185487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/890,754 US5503973A (en) 1992-05-29 1992-05-29 Method for inhibition of viral morphogenesis

Publications (1)

Publication Number Publication Date
ATE185487T1 true ATE185487T1 (de) 1999-10-15

Family

ID=25397107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93914329T ATE185487T1 (de) 1992-05-29 1993-06-01 Verfahren zur hemmung der viralen morphogenese

Country Status (11)

Country Link
US (3) US5503973A (de)
EP (1) EP0672192B1 (de)
JP (2) JPH08502162A (de)
AT (1) ATE185487T1 (de)
AU (1) AU673841B2 (de)
CA (1) CA2136958C (de)
DE (1) DE69326777T2 (de)
DK (1) DK0672192T3 (de)
ES (1) ES2139660T3 (de)
GR (1) GR3032237T3 (de)
WO (1) WO1993024660A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
AU6605196A (en) * 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
US20020034725A1 (en) * 1996-04-15 2002-03-21 W. Gillies Mckenna Sensitization of cells to radiation and and chemotherapy
WO1997043437A2 (en) * 1996-05-15 1997-11-20 The University Of Sheffield Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
MY141506A (en) * 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug
JP5042528B2 (ja) * 2003-02-12 2012-10-03 中外製薬株式会社 ウイルス治療薬
CN100502853C (zh) * 2003-02-12 2009-06-24 中外制药株式会社 抗病毒药
CA2522089A1 (en) * 2003-04-30 2004-11-11 Consejo Superior De Investigaciones Cientificas Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
MXPA06000294A (es) 2003-07-09 2006-04-18 Chugai Pharmaceutical Co Ltd Compuestos que tienen actividad contra el virus de la hepatitis c y procedimiento para producirlo.
US9592277B2 (en) 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
EP2408449A4 (de) 2009-03-18 2012-08-08 Univ Leland Stanford Junior Verfahren und zusammensetzungen zur behandlung von flaviviridae-virusinfektionen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US6627610B1 (en) * 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1997023256A1 (en) * 1995-12-22 1997-07-03 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US6015877A (en) * 1996-03-14 2000-01-18 President And Fellows Of Harvard College Compounds for inhibition of proteolysis
JP2002509428A (ja) * 1996-08-07 2002-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ａｆｃ１およびｒｃｅ１：イソプレニル化されたｃａａｘプロセシング酵素
CA2293270A1 (en) * 1997-06-11 1998-12-17 New York University Prenylcysteine carboxyl methyltransferase, dna encoding same, and a method of screening for inhibitors thereof
SE9703226D0 (sv) * 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) * 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction

Also Published As

Publication number Publication date
DE69326777T2 (de) 2000-03-09
EP0672192A4 (de) 1996-04-17
CA2136958C (en) 2011-03-22
EP0672192B1 (de) 1999-10-13
EP0672192A1 (de) 1995-09-20
JP4286764B2 (ja) 2009-07-01
WO1993024660A1 (en) 1993-12-09
AU4403293A (en) 1993-12-30
GR3032237T3 (en) 2000-04-27
US5876920A (en) 1999-03-02
JPH08502162A (ja) 1996-03-12
DK0672192T3 (da) 1999-12-27
ES2139660T3 (es) 2000-02-16
US5503973A (en) 1996-04-02
AU673841B2 (en) 1996-11-28
DE69326777D1 (de) 1999-11-18
JP2005124577A (ja) 2005-05-19
CA2136958A1 (en) 1993-12-09
US20080214471A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
DE69317015D1 (de) Adaptives Signalerkennungsverfahren zur Auswertung von Mehrfrequenz-Kodezeichen-Signalen
DE69331564D1 (de) Verfahren zur Spaltung von Cumolhydroperoxid
DE59310377D1 (de) Verfahren zur Nachprüfung von Sicherheitsabdrucken
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69329461D1 (de) Verfahren zur extraktion und reinigung von hamoglobin
DE69119610D1 (de) Verfahren zur mikro-einkapselung von hyperbarem gas
DE69326044D1 (de) Verfahren zur Erkennung von Sprachsignalen
DE3674365D1 (de) Verfahren zur pumpgrenzregelung von turbokompressoren.
ATE185487T1 (de) Verfahren zur hemmung der viralen morphogenese
EP0318562A4 (de) Verfahren zur selektiven inhibierung von hiv.
DE69303621D1 (de) Verfahren zur verbesserung der bioverfuegbarkeit von beta-carotine durch addition von kalzium und kohlenhydraten
DE59302738D1 (de) Verfahren zur Passivierung von Metallpigmenten
ATE176399T1 (de) Verfahren zur inaktivierung von spermien
DE69202962D1 (de) Verfahren zur Glycidylierung von Alkoholen.
DE59404520D1 (de) Verfahren zur Hydroformylierung von Butadien-1.3
DE68913581D1 (de) Verfahren zur Erkennung der Kontur eines Strahlenfelds.
DE69301353D1 (de) Verfahren zur Wiedergewinnung von Thiocyanat
DE69309843D1 (de) Verfahren zur Wiedergewinnung von Bortrifluorid
DE69411333D1 (de) Verfahren zur Rückgewinnung von verbrauchten Metallätzlösungen
DE69415837D1 (de) Verfahren zur Verminderung des freien Aldehydgehaltes von N-Alkylolamidmonomeren
DE3872632D1 (de) Vorrichtung zur diebstahlsicherung von autostereoanlagen.
ATE84317T1 (de) Verfahren zur reduktion von ketonen.
DE69301936D1 (de) Verfahren zur Behandlung von Rauchgas
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE69427290D1 (de) Verfahren zur induktion des todes von tumorzellen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee